Cancer in Patients With Familial Adenomatous Polyposis: A Nationwide Danish Cohort Study With Matched Controls

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 712 KB, PDF-dokument

Background & Aims
Familial adenomatous polyposis (FAP) is a hereditary disorder that predisposes patients to colorectal cancer (CRC). Prophylactic colectomy has greatly reduced the risk of CRC. However, new associations between FAP and the risk of other cancers have subsequently emerged. In this study, we assessed the risk of specific primary and secondary cancers among patients with FAP compared with matched controls.

Methods
All known patients with FAP up until April 2021 were identified in the nationwide Danish Polyposis Register and paired with 4 unique controls matched by birth year, sex, and postal code. The risk of overall cancers, specific cancer types, and risk of a second primary cancer was assessed and compared with controls.

Results
The analysis included 565 patients with FAP and 1890 controls. The overall risk of cancer was significantly higher for patients with FAP than for controls (hazard ratio [HR], 4.12; 95% confidence interval [CI], 3.28–5.17; P < .001). The increased risk was mainly due to CRC (HR, 4.61; 95% CI, 2.58–8.22; P < .001), pancreatic cancer (HR, 6.45; 95% CI, 2.02–20.64; P = .002), and duodenal/small-bowel cancer (HR, 14.49; 95% CI, 1.76–119.47; P = .013), whereas no significant difference was observed for gastric cancer (HR, 3.29; 95% CI, 0.53–20.23; P = .20). Furthermore, the risk of a second primary cancer was significantly higher for patients with FAP (HR, 1.89; 95% CI, 1.02–3.50; P = .042). Between 1980 and 2020, the risk of cancer among patients with FAP decreased by ∼50%.

Conclusions
Despite an absolute reduction in the risk of developing cancer among patients with FAP, the risk remained significantly higher than for the background population due to colorectal, pancreatic, and duodenal/small-bowel cancers.
OriginalsprogEngelsk
TidsskriftGastroenterology
Vol/bind165
Udgave nummer3
Sider (fra-til)573-581.e3
Antal sider9
ISSN0016-5085
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Funding The study received grant support from The Misse and Valdemar Risom Foundation.

Funding Information:
John Gásdal Karstensen, MD, PhD (Conceptualization: Equal; Data curation: Equal; Formal analysis: Equal; Investigation: Equal; Methodology: Equal; Writing – original draft: Lead; Writing – review & editing: Equal). Steffen Bülow, MD, DMSc (Conceptualization: Equal; Data curation: Equal; Formal analysis: Equal; Investigation: Equal; Methodology: Equal; Writing – review & editing: Equal). Helle Højen, Sec (Conceptualiation: Supporting; Data curation: Equal; Investigation: Supporting; Methodology: Equal; Writing – review & editing: Equal). Anne Marie Jelsig, MD, PhD (Conceptualization: Equal; Data curation: Equal; Investigation: Equal; Methodology: Equal; Writing – review & editing: Equal). Niels Jespersen, MD (Conceptualization: Equal; Data curation: Equal; Investigation: Equal; Methodology: Equal; Writing – review & editing: Equal). Klaus Kaae Andersen, MS, PhD (Formal analysis: Lead; Investigation: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Mads Damsgaard Wewer, MD (Data curation: Equal; Formal analysis: Equal; Investigation: Equal; Methodology: Equal; Writing – review & editing: Equal). Johan Burisch, MD, PhD, DMSc (Data curation: Equal; Formal analysis: Equal; Investigation: Equal; Methodology: Equal; Writing – review & editing: Equal). Hans Christian Pommergaard, MD, PhD, DMSc (Conceptualization: Equal; Data curation: Equal; Formal analysis: Equal; Investigation: Equal; Methodology: Equal; Writing – review & editing: Equal).

Publisher Copyright:
© 2023 The Authors

ID: 386373502